A Phase 1 interventional study of 2x500 mg Metformin (Glumetza) and 5 mg Linagliptin/1000 mg Metformin FDC in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-08-19.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the trial is to demonstrate the relative bioavailability of 2 newly developed fixed dose combination (FDC) tablets containing linagliptin \& metformin and the single tablets of linagliptin and metformin when administered singularly.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Any deviation from healthy condition
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3 single tablets under fed conditions
Drug: 2x500 mg Metformin (Glumetza) · Drug: 5 mg Linagliptin (Tradjenta)
2 FDC tablets under fasted conditions
Drug: 2 x 2.5 mg Linagliptin/750 mg Metformin FDC
4 single tablets under fasted conditions
Drug: 3x500 mg Metformin (Glumetza) · Drug: 5 mg Linagliptin (Tradjenta)
1 fixed dose combination(FDC) tablet under fasted conditions
Drug: 5 mg Linagliptin/1000mg Metformin FDC
3 single tablets under fasted conditions
Drug: 5 mg Linagliptin (Tradjenta) · Drug: 2 x 500 mg Metformin (Glumetza)
1 FDC tablet under fed conditions
Drug: 5 mg Linagliptin/1000 mg Metformin FDC
2 tablets
Drug pages: Linagliptin · Metformin
FDC tablet
1 tablet
1 tablet
3 tablets
1 tablet
2 tablets
Drug pages: Linagliptin · Metformin
FDC Tablet
2 FDC tablets
AUC0-72 of Linagliptin
Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval 0 to 72 Hours (AUC0-72). The shown geometric coefficients of variation (gCV) are the pooled intra-individual gCV - each over 2 treatment groups (FDC1000 fasted and L+M1000 fasted, FDC1000 fed and L+M1000 fed, FDC1500 fasted and L+M1500 fasted). The geometric means are actually adjusted geometric means.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40 min, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration at Day 1 of each treatment period
Cmax of Linagliptin
Maximum Measured Concentration (Cmax) of Linagliptin in plasma. The shown geometric coefficients of variation (gCV) are the pooled intra-individual gCV - each over 2 treatment groups (FDC1000 fasted and L+M1000 fasted, FDC1000 fed and L+M1000 fed, FDC1500 fasted and L+M1500 fasted). The geometric means are actually adjusted geometric means.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40 min, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration at Day 1 of each treatment period
AUC0-tz of Metformin
Area under the concentration-time curve of Metformin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz). The shown geometric coefficients of variation (gCV) are the pooled intra-individual gCV - each over 2 treatment groups (FDC1000 fasted and L+M1000 fasted, FDC1000 fed and L+M1000 fed, FDC1500 fasted and L+M1500 fasted). The geometric means are actually adjusted geometric means.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40 min, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration at Day 1 of each treatment period
Cmax of Metformin
Maximum Measured Concentration (Cmax) of Metformin in plasma. The shown geometric coefficients of variation (gCV) are the pooled intra-individual gCV - each over 2 treatment groups (FDC1000 fasted and L+M1000 fasted, FDC1000 fed and L+M1000 fed, FDC1500 fasted and L+M1500 fasted). The geometric means are actually adjusted geometric means.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40 min, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration at Day 1 of each treatment period
AUC0-infinity of Linagliptin
Area under the concentration-time curve of Linagliptin in plasma over the time interval from 0 extrapolated to infinity based on predicted last concentration values. The shown geometric coefficients of variation (gCV) are the pooled intra-individual gCV - each over 2 treatment groups (FDC1000 fasted and L+M1000 fasted, FDC1000 fed and L+M1000 fed, FDC1500 fasted and L+M1500 fasted). The geometric means are actually adjusted geometric means.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40 min, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration at Day 1 of each treatment period
AUC0-infinity of Metformin
Area under the concentration-time curve of Metformin in plasma over the time interval from 0 extrapolated to infinity based on predicted last concentration values. The shown geometric coefficients of variation (gCV) are the pooled intra-individual gCV - each over 2 treatment groups (FDC1000 fasted and L+M1000 fasted, FDC1000 fed and L+M1000 fed, FDC1500 fasted and L+M1500 fasted). The geometric means are actually adjusted geometric means.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40 min, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration at Day 1 of each treatment period
| Milestone | FDC1000 Fasted, Then L+M1000 Fasted | L+M1000 Fasted, Then FDC1000 Fasted | FDC1000 Fed, Then L+M1000 Fed | L+M1000 Fed, Then FDC1000 Fed | FDC1500 Fasted, Then L+M1500 Fasted | L+M1500 Fasted, Then FDC1500 Fasted |
|---|---|---|---|---|---|---|
| Started | 12 | 12 | 12 | 12 | 12 | 12 |
| Completed | 12 | 12 | 12 | 12 | 12 | 12 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | FDC1000 Fasted, Then L+M1000 Fasted | L+M1000 Fasted, Then FDC1000 Fasted | FDC1000 Fed, Then L+M1000 Fed | L+M1000 Fed, Then FDC1000 Fed | FDC1500 Fasted, Then L+M1500 Fasted | L+M1500 Fasted, Then FDC1500 Fasted |
|---|---|---|---|---|---|---|
| Started | 12 | 12 | 12 | 12 | 12 | 12 |
| Completed | 11 | 11 | 11 | 10 | 11 | 11 |
| Not completed | 1 | 1 | 1 | 2 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 1 | 0 | 1 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Elevated lab values (not clinic. sign.) | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 1 | 0 |
| Milestone | FDC1000 Fasted, Then L+M1000 Fasted | L+M1000 Fasted, Then FDC1000 Fasted | FDC1000 Fed, Then L+M1000 Fed | L+M1000 Fed, Then FDC1000 Fed | FDC1500 Fasted, Then L+M1500 Fasted | L+M1500 Fasted, Then FDC1500 Fasted |
|---|---|---|---|---|---|---|
| Started | 11 | 11 | 11 | 10 | 11 | 11 |
| Completed | 11 | 11 | 11 | 10 | 11 | 11 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval 0 to 72 Hours (AUC0-72). The shown geometric coefficients of variation (gCV) are the pooled intra-individual gCV - each over 2 treatment groups (FDC1000 fasted and L+M1000 fasted, FDC1000 fed and L+M1000 fed, FDC1500 fasted and L+M1500 fasted). The geometric means are actually adjusted geometric means.
| nmol*h/L | FDC1000 Fasted | L+M1000 Fasted | FDC1000 Fed | L+M1000 Fed | FDC1500 Fasted | L+M1500 Fasted |
|---|---|---|---|---|---|---|
| AUC0-72 of Linagliptin | 317.0 ± 8.0 | 319.2 ± 8.0 | 309.6 ± 5.5 | 304.9 ± 5.5 | 325.8 ± 5.1 | 322.9 ± 5.1 |
Maximum Measured Concentration (Cmax) of Linagliptin in plasma. The shown geometric coefficients of variation (gCV) are the pooled intra-individual gCV - each over 2 treatment groups (FDC1000 fasted and L+M1000 fasted, FDC1000 fed and L+M1000 fed, FDC1500 fasted and L+M1500 fasted). The geometric means are actually adjusted geometric means.
| nmol/L | FDC1000 Fasted | L+M1000 Fasted | FDC1000 Fed | L+M1000 Fed | FDC1500 Fasted | L+M1500 Fasted |
|---|---|---|---|---|---|---|
| Cmax of Linagliptin | 10.1 ± 17.1 | 10.6 ± 17.1 | 7.7 ± 13.0 | 7.9 ± 13.0 | 11.6 ± 16.5 | 10.7 ± 16.5 |
Area under the concentration-time curve of Linagliptin in plasma over the time interval from 0 extrapolated to infinity based on predicted last concentration values. The shown geometric coefficients of variation (gCV) are the pooled intra-individual gCV - each over 2 treatment groups (FDC1000 fasted and L+M1000 fasted, FDC1000 fed and L+M1000 fed, FDC1500 fasted and L+M1500 fasted). The geometric means are actually adjusted geometric means.
| nmol*h/L | FDC1000 Fasted | L+M1000 Fasted | FDC1000 Fed | L+M1000 Fed | FDC1500 Fasted | L+M1500 Fasted |
|---|---|---|---|---|---|---|
| AUC0-infinity of Linagliptin | 546.1 ± 12.8 | 526.5 ± 12.8 | 537.1 ± 9.6 | 510.0 ± 9.6 | 562.9 ± 13.5 | 581.1 ± 13.5 |
Area under the concentration-time curve of Metformin in plasma over the time interval from 0 extrapolated to infinity based on predicted last concentration values. The shown geometric coefficients of variation (gCV) are the pooled intra-individual gCV - each over 2 treatment groups (FDC1000 fasted and L+M1000 fasted, FDC1000 fed and L+M1000 fed, FDC1500 fasted and L+M1500 fasted). The geometric means are actually adjusted geometric means.
| ng*h/mL | FDC1000 Fasted | L+M1000 Fasted | FDC1000 Fed | L+M1000 Fed | FDC1500 Fasted | L+M1500 Fasted |
|---|---|---|---|---|---|---|
| AUC0-infinity of Metformin | 9037.6 ± 21.5 | 9326.5 ± 21.5 | 14031.3 ± 7.0 | 14069.7 ± 7.0 | 11037.7 ± 19.1 | 11512.2 ± 19.1 |
Area under the concentration-time curve of Metformin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz). The shown geometric coefficients of variation (gCV) are the pooled intra-individual gCV - each over 2 treatment groups (FDC1000 fasted and L+M1000 fasted, FDC1000 fed and L+M1000 fed, FDC1500 fasted and L+M1500 fasted). The geometric means are actually adjusted geometric means.
| ng*h/mL | FDC1000 Fasted | L+M1000 Fasted | FDC1000 Fed | L+M1000 Fed | FDC1500 Fasted | L+M1500 Fasted |
|---|---|---|---|---|---|---|
| AUC0-tz of Metformin | 8629.0 ± 21.8 | 8913.7 ± 21.8 | 13772.0 ± 7.4 | 13851.1 ± 7.4 | 10472.9 ± 18.5 | 10543.5 ± 18.5 |
Maximum Measured Concentration (Cmax) of Metformin in plasma. The shown geometric coefficients of variation (gCV) are the pooled intra-individual gCV - each over 2 treatment groups (FDC1000 fasted and L+M1000 fasted, FDC1000 fed and L+M1000 fed, FDC1500 fasted and L+M1500 fasted). The geometric means are actually adjusted geometric means.
| ng/mL | FDC1000 Fasted | L+M1000 Fasted | FDC1000 Fed | L+M1000 Fed | FDC1500 Fasted | L+M1500 Fasted |
|---|---|---|---|---|---|---|
| Cmax of Metformin | 1047.4 ± 25.5 | 1085.6 ± 25.5 | 1119.0 ± 8.1 | 1084.5 ± 8.1 | 1347.0 ± 29.3 | 1250.6 ± 29.3 |
Collected over 8 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FDC1000 Fasted | — | 0/23 (0%) | 1/23 (4.3%) |
| L+M1000 Fasted | — | 0/23 (0%) | 1/23 (4.3%) |
| FDC1000 Fed | — | 0/22 (0%) | 1/22 (4.5%) |
| L+M1000 Fed | — | 1/23 (4.3%) | 0/23 (0%) |
| FDC1500 Fasted | — | 0/23 (0%) | 3/23 (13%) |
| L+M1500 Fasted | — | 0/23 (0%) | 2/23 (8.7%) |
| Event | FDC1000 Fasted | L+M1000 Fasted | FDC1000 Fed | L+M1000 Fed | FDC1500 Fasted | L+M1500 Fasted |
|---|---|---|---|---|---|---|
| Road traffic accidentInjury, poisoning and procedural complications | 0/23 | 0/23 | 0/22 | 1/23 | 0/23 | 0/23 |
| Event | FDC1000 Fasted | L+M1000 Fasted | FDC1000 Fed | L+M1000 Fed | FDC1500 Fasted | L+M1500 Fasted |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 1/23 | 1/23 | 1/22 | 0/23 | 0/23 | 2/23 |
| NauseaGastrointestinal disorders | 0/23 | 0/23 | 0/22 | 0/23 | 2/23 | 1/23 |
| VomitingGastrointestinal disorders | 0/23 | 0/23 | 0/22 | 0/23 | 2/23 | 1/23 |
Treated set (TS) including all subjects who had been dispensed study medication and were documented to have taken at least 1 dose of study medication.
| Age, Continuous(years) | Total 1000 Fasted | Total 1000 Fed | Total 1500 Fasted | Total |
|---|---|---|---|---|
| Mean | 34.8 ± 9.3 | 30.6 ± 9.0 | 28.4 ± 7.1 | 31.3 ± 8.8 |
| Sex: Female, Male(Participants) | Total 1000 Fasted | Total 1000 Fed | Total 1500 Fasted | Total |
|---|---|---|---|---|
| Female | 8 | 8 | 14 | 30 |
| Male | 16 | 16 | 10 | 42 |
The record gives a start of May 2013, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Linagliptin · Metformin